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Abstract
CXCR4-using HIV-1 was previously shown to replicate more efficiently in a healthy donor-derived CD4+ CD38+ than in a CD4+ CD38− T-cell
subset after stimulation with interleukin (IL)-4. Here, we identified 3 cellular genes, which were expressed to a higher level in an IL-4-stimulated
CD38− subset. One of the 3 genes, RNF125/TRAC-1, was involved in the down-regulation of HIV-1 replication not only in cell lines, but also in
peripheral blood mononuclear cells. RNF125/TRAC-1 bears the RING finger domain, important for E3 ubiquitin protein ligase. Mutations in this
domain of RNF125/TRAC-1 led to the loss of HIV-1 down-modulatory activity, suggesting that E3 ligase activity is necessary. In addition, the results
of Northern blotting and reporter gene analysis indicated that RNF125/TRAC-1 function occurs at the viral transcription step. These results suggest
that RNF125/TRAC-1 could function to recruit host factor(s) controlling HIV-1 transcription to the ubiquitin–proteasome pathway.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Transcription; Replication; Host factorIntroduction
HIV-1 can enter into proliferating and quiescent CD4+ T
cells; interestingly resting Tcells do not support productive HIV-
1 infections (Stevenson et al., 1990; Tang et al., 1995; Zack,
1995). However, stimulation of T cells from the resting G0 to
G1b phase is sufficient to render the cells susceptible to HIV-1
infection and replication (Korin and Zack, 1998). Exposure of T
cells to cytokines, such as interleukin (IL)-2, IL-4, IL-7 or IL-15
that do not trigger cell division could also render them
susceptible to HIV-1 replication in the absence of any other
stimuli (Unutmaz et al., 1999). These findings suggest that
partial activation of resting T cells is sufficient and mitosis is not
necessary for HIV-1 replication.
Some reports suggested that HIV-1 infection leads to a shift
from a type 1 (IL-2, interferon-γ) to a type 2 (IL-4, IL-10)⁎ Corresponding author. Fax: +81 6 6879 8310.
E-mail address: shsana@biken.osaka-u.ac.jp (S. Shoji-Kawata).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.06.028cytokine profile with HIV-1 disease progression (Clerici and
Shearer, 1994; Maggi et al., 1994; Meyaard et al., 1994). For
example, the in vitro stimulation of peripheral blood mono-
nuclear cells (PBMCs) derived from HIV-1-infected individuals
at early stages of infection preferentially produced type 1 cyto-
kines, whereas that of PBMCs from HIV-1-infected individuals
at late stages preferentially produced type 2 cytokines, such as
IL-4 (Clerici et al., 1993). In fact, the increased production of
IL-4 in the course of HIV-1 infection has been reported (Klein
et al., 1997; Navikas et al., 1994). Other reports, however, have
not been able to document such a type 1 to type 2 cytokine shift
with disease progression (Estaquier et al., 1995; Romagnani and
Maggi, 1994).Meanwhile, the chemokine receptors CXCR4 and
CCR5 have been identified as the main co-receptors for HIV-1
(Berger et al., 1999). A predominance of CCR5-using (R5)
strains is observed during the early establishment of HIV-1
infection and throughout the asymptomatic period. Subse-
quently, in a substantial proportion of individuals, a shift to an
enrichment of CXCR4-using (X4) strains occurs, concomitant
192 S. Shoji-Kawata et al. / Virology 368 (2007) 191–204with accelerated CD4+ T-cell depletion (Connor et al., 1997;
Penn et al., 1999). In addition to some reports about increasing
type 2 cytokines and the X4 strain, the ratio of CD38+ to CD38−
T-cell subsets has been reported to increase during the course of
infection, as described below.
Human CD38 is a type II surface glycoprotein expressed on
premature hematopoietic cells, but its expression is detectable at
low levels on mature cells and again at high levels on activated
lymphocytes such as T cells, B cells, dendritic cells and natural
killer cells (Malavasi et al., 1994; Savarino et al., 2000). In HIV-
1-infected patients, CD38 is a prognostic marker of HIV-1
progression and high proportions of T cells expressing CD38
could be an indicator of disease progression (Savarino et al.,
2000). In contrast, the decreased proportions of T cells
expressing CD38 are a good indicator for the effectiveness of
highly active antiretroviral therapy (HAART) (Autran et al.,
1997; Vigano et al., 1998). Thus, CD38 expression on T cells
seems to be associated with HIV-1 progression.
We previously reported that X4 HIV-1 replicated more
efficiently in a CD4+ CD38+ than in a CD4+ CD38− T-cell
subset derived from healthy donors (Horikoshi et al., 2001). The
different susceptibility of CD38 subsets to X4 HIV-1 was
observed after stimulation of the cells with IL-4 (Horikoshi et al.,
2002). The expression levels of CD4 and CXCR4 were not
apparently different between these 2 subsets, suggesting that the
high susceptibility of the CD38+ subset to X4 HIV-1 was not
related with expression levels of the HIV-1 receptor and co-
receptor on the cell surface (Horikoshi et al., 2001). A possible
explanation for the different susceptibility of CD38 subsets to
X4 HIV-1 is the contribution of host cellular factors to down-
regulate HIV-1 replication in the CD38− subset and/or to up-
regulate HIV-1 replication in the CD38+ subset. In this study, we
performed GeneChip analysis to compare expression levels in
individual host genes between CD4+ CD38− and CD4+ CD38+
subsets before and after IL-4 stimulation. Three genes were
identified to show higher expressions in the CD38− subset after
IL-4 stimulation. One gene, named RNF125/TRAC-1, was
revealed to play an important role to down-modulate HIV-1
replication in primary PBMCs, probably at the transcription
step. RNF125/TRAC-1 bears the RING finger domain and has
E3 ubiquitin protein ligase activity. Mutations at the RING
domain actually affected the down-modulatory activity. Gen-
erally, the modification of proteins with ubiquitin chains by this
ligase is a prerequisite for their proteasomal degradation
(Hershko and Ciechanover, 1998; Pickart, 2001). Based on our
data, we propose the function of RNF125/TRAC-1 for the
ubiquitination of unidentified host cellular factor(s) that could be
crucially involved in the regulation of HIV-1 replication.
Results
Identification of host cellular genes that are expressed to a
higher level in a CD4+ CD38− than CD4+ CD38+ subset by
IL-4 stimulation
We previously reported that an IL-4-stimulated CD4+ CD38+
subset showed higher susceptibility to X4 HIV-1 than an IL-4-stimulated CD4+ CD38− subset (Horikoshi et al., 2002; Li et al.,
2005). In addition, this difference between CD38 subsets was
shown to be derived from the events after the integration step (Li
et al., 2005). In this study, we first confirmed this difference in
infection rate between IL-4-stimulated CD38+ and CD38−
subsets with the VSVG/HIV-1 possessing luciferase gene (Fig.
1A). CD38 subsets in Set 1 and Set 2 experiments were prepared
from the resting CD4+ T-cell fraction isolated from healthy
donor-derived PBMCs. The subsets were cultured with or
without IL-4 for 3 days before infection with VSVG/HIV-1. As
expected, in both Set 1 and Set 2 experiments, luciferase activity
remained low in IL-4-unstimulated subsets and was at a similar
level in both subsets. In contrast, when the CD38+ subset was
stimulated with IL-4 followed by infection, luciferase activity
was increased approximately 6- and 24-fold in both Set 1 and Set
2 experiments, respectively (Fig. 1A). One possible explanation
for this different susceptibility between CD38 subsets to X4
HIV-1 may be the difference in cellular host factors that could be
involved in viral replication. Therefore, we compared expression
levels in individual human genes by GeneChip analysis between
CD38+ and CD38− subsets, both of which were unstimulated
and stimulated with IL-4 (data not shown). The results showed
that 122 cellular genes were up-regulated more than 2-fold in the
CD38+ subset by IL-4 stimulation, which corresponded to
∼0.37% of all genes on the GeneChip. In addition, 49 cellular
genes were up-regulated more than 2-fold in the CD38− subset
by IL-4 stimulation, which corresponded to∼0.15% of all genes
on the GeneChip. Among these genes, the common up-regulated
genes in CD38+ and CD38− subsets were 26 genes, which
corresponded to ∼21% of all up-regulated genes in CD38+ and
to ∼53% in CD38− subset (Fig. 1B). The other ∼79% of up-
regulated genes in CD38+ and the other ∼47% of up-regulated
genes in CD38− subset may be involved in the different
susceptibility to HIV-1 between CD38+ and CD38− subsets. At
least, it was suggested that the other ∼47% up-regulated genes
in CD38− subset could not up-modulate HIV-1 replication and
may function to down-modulate HIV-1 replication. In this study,
we focused on down-modulators of HIV-1 replication and
performed the additional GeneChip analysis. Among the up-
regulated genes in CD38− but not in CD38+ by IL-4 stimulation,
only 3 genes (IL-9, M-CSF and RNF125/TRAC-1) showed
higher expression levels in IL-4-stimulated CD38− than in IL-4-
stimulated CD38+ subset (Fig. 1B and Table 1). Therefore we
further analyzed the 3 genes (IL-9,M-CSF and RNF125/TRAC-
1) more in detail.
RT–PCR of 3 genes identified by GeneChip analysis
To confirm the GeneChip data, CD4+ CD38 subsets were
similarly prepared and stimulated with IL-4 for 3 days, then
subjected to semi-quantitative RT–PCR and quantitative PCR
analyses (Fig. 2A). The results showed a clear difference in IL-9,
M-CSF and RNF125/TRAC-1 between IL-4-stimulated CD38
subsets: 8.2-fold, 3.4-fold and 3.9-fold higher expressions,
respectively (Fig. 2A, lower panel). Thus, the results of real-time
PCR analysis were essentially consistent with those of
GeneChip analysis. Since M-CSF and RNF125/TRAC-1 were
Table 1
Increased expression of genes in CD4+ CD38− subsets by IL-4-stimulation
GenBank™ Name Description IL-4/None a
(fold change)
CD38−/CD38+ b
(fold change)
NM_000590 IL-9 Interleukin 9 2.6 5.7
M37435 M-CSF Macrophage-specific
colony-stimulating
factor
2.2 2.7
NM_017831 RNF125 RING finger
protein 125
4.3 2.4
a The levels of the indicated transcripts in IL-4-stimulated CD4+ CD38−
subset relative to that in IL-4-unstimulated CD4+ CD38− subset.
b The levels of the indicated transcripts in IL-4-stimulated CD4+ CD38−
subset relative to that in IL-4-stimulated CD4+ CD38+ subset.
Fig. 1. Identification of host cellular genes that are expressed to a higher level in a CD4+ CD38− than CD4+ CD38+ subset by IL-4 stimulation. (A) CD4+ CD38− and
CD4+ CD38+ subsets were cultured with or without IL-4 for 3 days. 1×106 cells were exposed to VSVG/HIV-1 (30 ng of p24 Gag) for 1 h and cultured with IL-2. After
a further 2 days, luciferase activity was measured. Two independent experiments were performed: Set 1, CD4+ CD38 subsets from PBMCs prepared from one healthy
donor; and Set 2, CD4+ CD38 subsets from pooled PBMCs prepared from another 2 healthy donors. (B) Diagram shows the distribution of genes regulated among IL-
4-unstimulated and -stimulated CD4+ CD38 subsets.
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CD38+ subset and their mRNA levels were relatively high, we
focused on these 2 genes. We examined the possible induction of
these 2 gene expressions in the CD38 subsets by IL-4
stimulation. The CD4+ CD38 subsets were cultured with and
without IL-4 for 3 days and subjected to semi-quantitative RT–
PCR and real-time PCR analyses (Fig. 2B). The result showed
that the expressions of M-CSF and RNF125/TRAC-1 were
significantly up-regulated by IL-4 stimulation in the CD38−
subset, whereas the up-regulation in the CD38+ subset was only
faint. Similar results were obtained in CD38 subsets indepen-
dently prepared from 2 other healthy donors (data not shown).
Although M-CSF is known to be expressed in various cells,
including lymphocytes, and to be induced by IL-4 in T cells
(Praloran, 1991; Rettenmier and Sherr, 1989), the expression of
the M-CSF receptor, c-fms, is restricted only to the monocyte–
macrophage lineage (Datta et al., 1992; Weber et al., 1989). On
the other hand, RNF125/TRAC-1 mRNA was reported to be
predominantly expressed in lymphoid tissues, especially T cells
(Zhao et al., 2005). Therefore, we further characterized the latter
gene more in detail. The expression level of RNF125/TRAC-1
in PBMCs at the mRNA level was significantly higher than
various cell lines including 293T and Jurkat cell lines (data not
shown), as previously reported (Zhao et al., 2005). In addition,Western blotting also showed a high expression of RNF125/
TRAC-1 in CD38− subset after stimulation with IL-4 (Fig. 2C).
Down-modulatory effect of RNF125/TRAC-1 on VSVG/HIV-1
replication
To examine the possible contribution of RNF125/TRAC-1 to
the down-modulation of HIV-1 replication, we used lentiviral
vector in order to transfer this gene into Jurkat T cells, because
the lentiviral vector we used is generally believed not to affect
Fig. 2. RT–PCR of 3 genes identified by GeneChip analysis. (A) RNAwas extracted from CD4+ CD38 subsets stimulated with IL-4 for 3 days. The results of semi-
quantitative RT–PCR analysis are shown (upper panel). The cDNA equivalent to 50 ng of RNA was amplified using gene-specific primers. Further, the results
measured by real-time RT–PCR analysis are shown (lower panels). The values were normalized to GAPDH and are shown as a fold increase by comparing them to
mRNA levels in the CD4+ CD38+ subset. Error bars represent standard deviations from 3 independent PCR reactions. (B) RNAwas extracted from the CD4+ CD38−
subset stimulated or unstimulated with IL-4 for 3 days and was subjected to semi-quantitative RT–PCR analysis. cDNA equivalent to 100 ng of RNAwas amplified
using gene-specific primers. Further, the results measured by real-time RT–PCR analysis are shown. The values were normalized to GAPDH and are shown as a fold
increase by comparing them to mRNA levels in IL-4-unstimulated CD4+ CD38 subsets. (C) The expression of RNF125/TRAC-1 protein in IL-4-unstimulated and
-stimulated CD4+ CD38 subsets was detected by Western blotting using anti-RNF125/TRAC-1 antibody. Set 1 and Set 2 indicate the IL-4-stimulated CD4+ CD38
subsets derived from PBMCs of different healthy donors. Control indicates the lysates from 293T cells transfected with RNF125/TRAC-1 expression plasmid, which
does not contain a Flag epitope tag.
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et al., 1999). As a control, a lentiviral vector containing the GFP
gene was used. Under the conditions that GFP expression in
Jurkat cells was detectedmore than 90% at 24 h post-transduction,
the RNF125/TRAC-1 gene was transduced into the cells by the
lentiviral vector. As expected, more than 90% of the cells
expressed RNF125/TRAC-1 at 24 h post-transduction byimmunofluorescence staining (Fig. 3A, left panel). In addition,
the data showed punctate staining pattern. To investigate its
subcellular localizationmore in detail, 293Tcells were transfected
with RNF125/TRAC-1 expression plasmid. At 24 h post-
transfection, RNF125/TRAC-1 protein was found to be localized
in a punctate cytoplasmic distribution (data not shown). Next,
transduced cells with the RNF125/TRAC-1 or GFP gene were
Fig. 3. Down-modulatory effect of RNF125/TRAC-1 on VSVG/HIV-1 replication. (A) 5×105 Jurkat T cells were transduced by lentiviral vector containing GFP or
RNF125 (RNF125/TRAC-1-FLAG) (30 ng of p24 Gag). At 24 h post-transduction, immunofluorescence staining was performed using anti-FLAG antibody (left
panels). At 24 h post-transduction, cells were infected with VSVG/HIV-1 (10 ng of p24 Gag) (right panel). At 24 h post-inoculation, luciferase activity was measured.
The relative luciferase activities are shown as a fold increase by comparing them to the activities of GFP-transduced cells. ∗Pb0.01, for significant difference
compared to GFP-transduced cells, determined by Student's paired t-test. Error bars represent standard deviations from 6 independent experiments. (B) Jurkat T cells
were transduced by lentiviral vector containing GFP or RNF125 (RNF125/TRAC-1-FLAG) (30 ng of p24 Gag). At 48 h post-transduction, cell proliferation was
determined by the cell proliferation assay. Error bars represent standard deviations from 3 independent experiments. Nocodazole, cells treated with nocodazole as a
positive control for cell proliferation inhibition. (C) 293T cells were transfected with 100 nM of RNF125 (RNF125/TRAC-1-specific) or GAPDH-specific siRNA, or
cells were cotransfected with 100 nM of RNF125 (RNF125/TRAC-1-specific) siRNA and a plasmid expressing RNF125-escape(1). At 48 h post-transfection, RNA
was extracted, and semi-quantitative RT–PCR analysis was performed (left panel). The cDNA equivalent to 140 ng of RNAwas amplified using gene-specific primers.
At 24 h post-transfection, 293Tcells were infected with VSVG/HIV-1 (25 ng of p24 Gag) (right panel). At 27 h post-inoculation, luciferase activity was measured. The
relative luciferase activities are shown as a fold increase by comparing them to the activities of cells transfected with GAPDH-specific siRNA. Errors bars represent
standard deviations of 3 independent experiments. si(1), RNF125/TRAC-1-specific siRNA which targets nucleotides 205 to 225; si(2), RNF125/TRAC-1-specific
siRNA which targets nucleotides 525 to 545 of RNF125/TRAC-1 cDNA sequence (GenBank™ Accession Number: NM_017831); RNF125-escape(1), RNF125
(RNF125/TRAC-1-FLAG) expression plasmid containing silent mutations at the recognition site of si(1).
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expressingRNF125/TRAC-1 showed decreased luciferase activity
by approximately 50% compared to cells expressing GFP (Fig.
3A, right panel). In addition, the proliferation of cells expressing
RNF125/TRAC-1 was not different from that of cells expressingGFP (Fig. 3B). The trypan blue exclusion also indicated no
apparent cell death among cells expressing RNF125/TRAC-1 or
GFP (data not shown). Thus, the ectopic expression of
RNF125/TRAC-1 was shown to down-modulate HIV-1 replica-
tion without host cell damage. Therefore, we next examined the
196 S. Shoji-Kawata et al. / Virology 368 (2007) 191–204effect of the down-regulation of endogenous RNF125/TRAC-1
using siRNA specific toRNF125/TRAC-1. As a control, siRNA to
GAPDH was used.
Before HIV-1 infection, we confirmed the silencing effects
of these siRNAs to RNF125/TRAC-1. 293T cells were
transfected with the siRNA, and the expression level of
RNF125/TRAC-1 mRNA was estimated by semi-quantitative
RT–PCR analysis (Fig. 3C). RNF125/TRAC-1-specific [si(1)
and si(2)], but not GAPDH-specific siRNA (siGAPDH),
significantly decreased the level of RNF125/TRAC-1 mRNA
in 293T cells (Fig. 3C, left panel). As expected, si(1) did not
inhibit the expression of a RNF125-escape(1) expression
plasmid, which has 5 silent mutations in the target region of
the si(1) (Fig. 3C, left panel). Under these conditions, the
293T cells at 24 h after treatment as above were infected
with VSVG/HIV-1. At 24 h post-inoculation, luciferase
activity was measured. The cells transfected with RNF125/
TRAC-1-specific siRNAs showed increased luciferase activityFig. 4. Significance of E3 ligase activity of RNF125/TRAC-1 on its down-modulat
domain in RNF125 (RNF125/TRAC-1). The mutation sites for constructing RNF1
cotransfected with indicated amounts of RNF125 (RNF125/TRAC-1-FLAG) or its m
control plasmid. Transfection was carried out under the condition to equalize the total
particle in the culture supernatant was determined by HIV-1 Gag p24 ELISA (left pan
p24 level of cells transfected with HIV-1 proviral DNA. Error bars represent standard
lysates were analyzed by Western blotting to detect HIV-1 gp120, PARP, α-tubulin, G
Lane 1, 293T cells transfected with pCMV-GFP; lanes 2–6, 293T cells cotransfecte
TRAC-1-FLAG), C37A-FLAG and C37/40A-FLAG expression plasmids, respective
induction.compared to siGAPDH-transfected cells: 2.1- and 2.7-fold
increases by transfection with si(1) and si(2), respectively
(Fig. 3C, right panel). The increased activity observed after
transfection of si(1) was diminished when the 293T cells
were transfected with a plasmid expressing RNF125-escape
(1) (Fig. 3C, right panel). These results indicate that
RNF125/TRAC-1 has a down-modulatory effect on HIV-1
replication.
Significance of E3 ligase activity of RNF125/TRAC-1 on its
down-modulatory effect on HIV-1 replication
The RNF125/TRAC-1 gene encodes a protein of 232 amino
acids (aa), containing a RING consensus sequence between aa
residues 37 to 75 (Fig. 4A). The RING finger domain is defined
by 8 cysteines and histidines that coordinate 2 zinc ions. The
proteins bearing this motif have either a cysteine [C3HC4 RING
(RING-HC)] or a histidine [C3H2C3 RING (RING-H2)] in theory effect on HIV-1 replication. (A) Amino acid sequence of the RING finger
25/TRAC-1 mutants, C37A and C37/40A, are indicated. (B) 293T cells were
utant expression plasmid, 0.7 μg of HIV-1 proviral DNA and pCMV-GFP as a
DNA amount by adding empty plasmid DNA. At 48 h post-transfection, the virus
el). The relative p24 levels are shown as a percentage by comparing them to the
deviations from 3 independent experiments. At 48 h post-transfection, whole-cell
FP and RNF125 (RNF125/TRAC-1-FLAG) or its mutant proteins (right panel).
d with HIV-1 proviral DNA and pCMV-GFP together with RNF125 (RNF125/
ly; lane 7, cells treated with actinomycin D as a positive control for apoptosis
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sequences, RNF125/TRAC-1 belongs to the RING-HC cate-
gory. Additionally, the presence of a RING finger domain
suggested that RNF125/TRAC-1 could function as an E3
ubiquitin protein ligase. Indeed, an in vitro ubiquitin assay
confirmed that RNF125/TRAC-1 is an E3 ligase (data not
shown), as previously reported (Zhao et al., 2005). In order to
investigate whether the E3 ligase activity of RNF125/TRAC-1 is
necessary to down-modulate HIV-1 replication, we replaced the
first cysteine or the first and second cysteines of the RING
finger domain with alanine in order to create RNF125/TRAC-1
mutants, C37A and C37/40A, respectively (Fig. 4A), according
to previous papers (Stremlau et al., 2004; Waterman et al.,
1999). In vitro ubiquitin assays confirmed that these 2 mutantsFig. 5. Down-modulatory effect of RNF125/TRAC-1 on HIV-1 transcription. (A) 29
amounts of RNF125 (RNF125/TRAC-1-FLAG) or C37A-FLAG expression plasmid.
Individual viral transcripts were detected by Northern blotting using a 32P-labeled
transcripts are indicated. Ethidium bromide-staining patterns of 28S and 18S rRNAs
stably expressing pLTR-Luc were transfected with the indicated amounts of RNF12
cells stably expressing pRL-TK (TK-Luc), pRL-SV40 (SV40-Luc) and pCMV-Luc w
expression plasmid. (D) 293T cells stably expressing pLTR-Luc were transfected w
expression plasmid. In (B–D), transfection was carried out under the condition to e
transfection, luciferase activity was measured. The relative luciferase activities are sho
empty plasmid DNA. Error bars represent standard deviations of 3 independent expdramatically decreased E3 ligase activity (data not shown), and
it was consistent with previous paper (Zhao et al., 2005).
293Tcells were cotransfected with an HIV-1 molecular clone
(pNL4-3), a plasmid containing GFP gene under the control of
the CMV promoter (pCMV-GFP) as a control and the RNF125/
TRAC-1 or the mutant expression plasmid. It was revealed that
RNF125/TRAC-1 significantly decreased the release of viral
particles in the supernatant in a dose-dependent manner (Fig. 4B,
left panel). On the other hand, C37A and C37/40A did not
decrease the production of viral particles in the supernatant. In
this assay, reinfection does not occur, because of the absence of
the CD4 receptor on 293T cells. Western blotting revealed a
decrease in the HIV-1 gp120 level in cells expressing RNF125/
TRAC-1 (Fig. 4B, right panel, lanes 3 and 4), suggesting that3T cells were cotransfected with 0.7 μg of HIV-1 proviral DNA and indicated
At 48 h post-transfection, the cells were harvested, and total RNAwas extracted.
nef fragment as a probe (upper panel). The positions of 9.2, 4.3, and 2.0 kb
in the same sample are shown as a loading control (lower panel). (B) 293T cells
5 (RNF125/TRAC-1-FLAG) or C37/40A-FLAG expression plasmid. (C) 293T
ere transfected with the indicated amounts of RNF125 (RNF125/TRAC-1-FLAG)
ith Tat-HA and/or the indicated amounts of RNF125 (RNF125/TRAC-1-FLAG)
qualize the total DNA amount by adding empty plasmid DNA. At 24 h post-
wn as a fold increase by comparing them to the activities of cells transfected with
eriments.
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and release of viral particles into the supernatant. In contrast, the
expression of RNF125/TRAC-1 did not affect the expression of
GFP (Fig. 4B, right panel). PARP (poly(ADP-ribose) polymer-
ase) was not cleaved in cells transfected with RNF125/TRAC-1
expression plasmid (Fig. 4B, right panel, lanes 3 and 4),
suggesting that the decreased production of viral particles was
not due to apoptosis.
Down-modulatory effect of RNF125/TRAC-1 on HIV-1
transcription
To further elucidate the down-modulatory effect of RNF125/
TRAC-1 on HIV-1 replication, 293T cells were cotransfected
with the HIV-1 molecular clone together with the RNF125/
TRAC-1 expression plasmid. At 48 h post-transfection, theFig. 6. Down-modulatory effect of RNF125/TRAC-1 on HIV-1 replication in PBMC
healthy donor were stimulated with IL-2, IL-4 or PHA for 3 days. The 1×106 PBMCs
1-FLAG) or C37/40A-FLAG (50 ng of p24 Gag). The transduced cells were cultured
GFP, RNF125/TRAC-1 (RNF125/TRAC-1-FLAG) or C37/40A-FLAG gene by lentiv
(30 ng of p24 Gag). At 2 days post-inoculation, luciferase activity was measured. Th
the activities of GFP-transduced cells. Sets 1 to 9 indicate the results obtained fromaccumulated viral RNA levels in the cells were compared by
Northern blotting (Fig. 5A). The results showed that RNF125/
TRAC-1 expression induced a significant reduction in all kinds
of HIV-1 transcripts including the 9.2 kb unspliced, the 4.3 kb
single-spliced and the 2.0 kb double-spliced RNAs in a dose-
dependent manner (Fig. 5A, lanes 2–4). In contrast, C37A did
not induce such reduction, but rather significantly increased all
kinds of viral transcripts (Fig. 5A, lanes 2 and 5). Furthermore, in
order to investigate the effect of RNF125/TRAC-1 on the
transcription of integrated HIV-1 LTR promoter, 293T cells
stably expressing an HIV-1 LTR-driven luciferase gene (293T-
LTR cells) were transfected with the RNF125/TRAC-1 expres-
sion plasmid, then luciferase activity was measured at 24 h post-
transfection (Fig. 5B, left panel). RNF125/TRAC-1 was shown
to down-modulate the LTR-driven gene expression by approxi-
mately 80%. In contrast, when 293T cells stably expressing TK-s from healthy donors. (A) Experimental scheme. PBMCs prepared from one
were transduced by lentiviral vector containingGFP, RNF125 (RNF125/TRAC-
with IL-2. (B) PBMCs stimulated with IL-2, IL-4 or PHAwere transduced with
iral vector. The cells were cultured for 2 days and infected with VSVG/HIV-1
e relative luciferase activities are shown as a fold increase by comparing them to
PBMCs independently prepared from different healthy donors.
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RNF125/TRAC-1 expression plasmid, RNF125/TRAC-1 down-
modulated TK-driven and CMV-driven gene expressions by
approximately 10% and 20%, respectively (Fig. 5C). RNF125/
TRAC-1 did not down-modulate SV40-driven gene expression
(Fig. 5C). Next, we investigated the possible correlation between
the down-modulatory effect of RNF125/TRAC-1 on the
integrated HIV-1 LTR-driven transcription and the E3 ligase
activity of RNF125/TRAC-1. For this, 293T cells were trans-
fected with the C37/40A expression plasmid. The C37/40A
mutant did not down-modulate the LTR-driven gene expression
(Fig. 5B). Interestingly, RNF125/TRAC-1 modulated the HIV-1
LTR-driven gene expression in the presence of Tat expression
(Fig. 5D).
Down-modulatory effect of RNF125/TRAC-1 on HIV-1
replication in PBMCs from healthy donors
In order to investigate whether RNF125/TRAC-1 affects
HIV-1 replication in primary cells, the RNF125/TRAC-1 gene
was transferred into PBMCs using the lentiviral vector. Since
the lentiviral vector can not transfer the target gene into resting
PBMCs (Maurice et al., 2002), healthy donor-derived PBMCs
were stimulated with PHA, IL-2 or IL-4 for 3 days (Unutmaz
et al., 1999). Using preliminary experiments for the transduction
efficiency of lentiviral vector into PBMCs, the best conditions
were determined: by the schedule shown in Fig. 6A, the GFP-
containing lentiviral vector was able to express GFP in the
PHA-stimulated PBMCs by more than 50% at 4 days post-
inoculation (data not shown). Under the same conditions,
PBMCs were transduced with the RNF125/TRAC-1 gene by the
lentiviral vector. At 2 days post-transduction, the cells were
infected with VSVG/HIV-1 possessing the luciferase gene.
When luciferase activity was measured at 2 days post-
inoculation with VSVG/HIV-1, it was revealed that at least 6
among 9 PBMCs prepared from different healthy donors
showed significant reduction of VSVG/HIV-1 replication by
RNF125/TRAC-1 expression, expressed as the relative activity
to that of GFP expression (Fig. 6B). PHA-stimulated PBMCs
were similarly transduced with the C37/40Amutant gene by use
of a lentiviral vector and then infected with VSVG/HIV-1. The
results showed that the expression of the C37/40A rather
enhanced VSVG/HIV-1 replication in all 4 PBMCs examined
(Fig. 6B). These results suggest that RNF125/TRAC-1 could be
involved in the down-modulation of HIV-1 replication in
primary cells.
Discussion
In this paper, we demonstrated that a novel host protein
possessing E3 ubiquitin protein ligase activity, RNF125/TRAC-
1, could exhibit a down-modulatory effect on HIV-1 replication.
The down-modulatory activity of this protein even in the assay
using an HIV-1 LTR-driven reporter gene was detected,
suggesting its antiviral effect on the viral transcription step.
We had shown that X4 HIV-1 could replicate in the CD4+
CD38+ subset at a higher rate than the CD4+ CD38− subset afterIL-4 stimulation for 3 days (Horikoshi et al., 2002). In this study,
we also found that VSVG/HIV-1 replicated more efficiently in
the CD38+ than in the CD38− subset.We previously showed that
there was no apparent difference between both CD38 subsets in
their cell proliferation rates before and after IL-4 stimulation (Li
et al., 2005), which was consistent with the report that only
5–7% of resting T cells had entered the cell cycle by IL-4
stimulation (Unutmaz et al., 1999). Thus, the difference in
susceptibility of CD38 subsets to HIV-1 might not be associated
with cell proliferation. In addition, we also reported that the
expression levels of CD4 and CXCR4 were not significantly
different between IL-4-unstimulated CD38− and CD38+ subsets
and also between IL-4-stimulated CD38− and CD38+ subsets,
since IL-4 stimulation up-regulated CXCR4 expression on both
CD38 subsets at a similar rate (Horikoshi et al., 2002),
suggesting that the receptor and co-receptor expression were
not directly correlated with this difference in viral replication
between both CD38 subsets. Therefore, we tried to find novel
cellular factor(s) that negatively regulate HIV-1 replication in the
CD38− subset and also positively regulate HIV-1 replication in
the CD38+ subset after IL-4 stimulation. We compared more
than 30,000 cellular genes expressed between IL-4-stimulated
CD38− and CD38+ subsets. Consequently, the results of
GeneChip analysis finally prompted us to select the 3 genes,
which may down-modulate HIV-1 replication. Following the
characterization of 3 individual genes by RT–PCR, the assays of
viral replication revealed that one of the genes, RNF125/TRAC-1,
exhibited a down-modulatory effect on viral replication,
probably at the transcription step.
HIV-1 encodes a transactivator protein Tat, which enhances
viral transcription (Bieniasz et al., 1999; Wei et al., 1998).
Therefore, we examined whether RNF125/TRAC-1 modulates
transcription in the presence of Tat. By cotransfection of the
293T-LTR cells with Tat and RNF125/TRAC-1 expression plas-
mids, RNF125/TRAC-1 was shown to down-modulate reporter
gene expression in the presence of Tat. However, the effect of
RNF125/TRAC-1was moderate, compared to that in the absence
of Tat. One possible explanation may be that Tat partially
counteracts the down-regulation effect of RNF125/TRAC-1 on
HIV-1 LTR promoter activity. It was reported that Hdm2 binds to
Tat and mediates the ubiquitination of the Tat (Bres et al., 2003).
However, our preliminary experiments in 293T cells cotrans-
fected with RNF125/TRAC-1 and Tat expression plasmids
followed by immunoprecipitation showed no interaction
between Tat and RNF125/TRAC-1 (data not shown). The co-
expression of RNF125/TRAC-1 and Tat proteins in 293T cells
showed that RNF125/TRAC-1 did not affect the stability of Tat
protein. Additionally, the expression of RNF125/TRAC-1 in
293T cells showed that RNF125/TRAC-1 did not affect the
stability of cyclin T1 protein, although it was reported that cyclin
T1, a mediator of Tat function, is down-regulated by protea-
some-mediated proteolysis (Liou et al., 2004).
Previously, the immunological function of RNF125/TRAC-1
was reported (Zhao et al., 2005), i.e., positive regulation of T-cell
activation as shown by T-cell receptor (TCR)-mediated CD69
up-regulation. Since it is generally believed that the activation
state of host cells stimulates HIV-1 replication (Stevenson et al.,
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immunological function may contradict our results in this study;
however, there are 2 possible explanations for this discrepancy:
(i) The RNF125/TRAC-1 level for the T-cell activation function
may be different from that for the modulatory function of HIV-1
replication. Their conclusion of RNF125/TRAC-1 for T-cell
activation was derived from evidence that the expression of the
carboxyl-terminal truncation of RNF125/TRAC-1 as dominant-
negative RNF125/TRAC-1 inhibits TCR-mediated CD69 up-
regulation in Jurkat T cells. However, they also simultaneously
found no more enhancement of TCR-mediated CD69 up-
regulation in Jurkat cells by the ectopic expression of full-length
RNF125/TRAC-1 in addition to the natural level of RNF125/
TRAC-1. In addition, antisense oligonucleotides to RNF125/
TRAC-1 also inhibit the TCR-mediated activation of primary T
cells. These results imply that the endogenous level of RNF125/
TRAC-1 might be saturated as a positive regulator of T-cell
activation. In contrast, the ectopic expression of RNF125/
TRAC-1 down-modulated HIV-1 replication in Jurkat T cells in
this study, suggesting that endogenous RNF125/TRAC-1 is not
saturated as a down-modulator of HIV-1 replication. (ii) Another
possibility is the different mechanism between RNF125/TRAC-
1 functions, T-cell activation and down-modulation of HIV-1
replication. It has been reported that E3 ligase recognizes
specific protein substrates (Hershko and Ciechanover, 1998;
Pickart, 2001). Therefore, substrates recognized by RNF125/
TRAC-1 to function as a T-cell activator could be different from
those functioning as a down-modulator of HIV-1 replication. In
addition, it was reported that RNF125/TRAC-1 catalyzes the
formation of Lys48- and Lys63-linked polyubiquitin chains,
indicating that RNF125/TRAC-1 activates degradative and
regulatory ubiquitin-dependent pathways, respectively (Zhao
et al., 2005). Thus, RNF125/TRAC-1 may differently regulate
these 2 functions by targeting different substrates and also by
using degradative and regulatory pathways. It would also be
interesting to see whether HIV-1 replication is further decreased
by ISG15 (Desai et al., 2006). A future experiment to be con-
sidered would be to delineate Lys48 (degradation) vs. Lys63
(regulation) (Badciong and Haas, 2002) in RNF125/TRAC-1 in
order to see if there is HIV-1 down-modulation.
RNF125/TRAC-1 bears a RING finger domain at aa residues
37 to 75. The in vitro assay revealed that RNF125/TRAC-1 has
an E3 ubiquitin protein ligase activity (data not shown), as
previously reported (Zhao et al., 2005). In cells transfected with
the HIV-1 molecular clone, C37A and C37/40A did not down-
modulate the production of HIV-1 particles but rather enhanced
viral production. Northern blotting and reporter gene analysis
also showed similar results. One possible explanation is that
these mutants function as dominant negatives in our experi-
mental system, although a previous paper (Zhao et al., 2005) did
not show the dominant negative effect of theses mutants in T-cell
activation. Another possible explanation is that RNF125/TRAC-
1's target protein functions to up-regulate HIV-1 replication.
Therefore, ectopic expression of RNF125/TRAC-1might down-
modulate the HIV-1 up-regulator(s) and resulted in down-
modulation of HIV-1 replication. In contrast, ectopic expression
of RNF125/TRAC-1 mutants might not down-modulate theHIV-1 up-regulator(s) and resulted in no down-modulation of
HIV-1 replication. These results indicated that the E3 ligase
activity of RNF125/TRAC-1 was necessary to down-modulate
HIV-1 transcription. It has been reported that the treatment of
human cells with a proteasome inhibitor enhanced the efficiency
of HIV-1 infection in the early phase (Schwartz et al., 1998),
suggesting that processes involving ubiquitination play impor-
tant roles in the inhibition of HIV-1 replication. In addition,
several studies found that proteasome pathways are involved
in the regulation of nuclear factor-κB (Ganesh et al., 2003;
Fouchier et al., 1997) that affects HIV-1 replication. It is indi-
cated that other E3 ligases, TRIM5α (Stremlau et al., 2004) and
POSH (Alroy et al., 2005), inhibit and enhance HIV-1
replication, respectively. The ubiquitin ligase RNF125/TRAC-1
may present another new role for E3 ligases. Also, a similar
RING finger ubiquitin ligase motif has been found on MdmX
and is capable of synergistically enhancing Mdm2 ubiquitina-
tion (Badciong and Haas, 2002). Based on our data about the
down-modulatory effects of RNF125/TRAC-1 on HIV-1 replica-
tion not only in cell lines but also in primary PBMCs, certain
unidentified factor(s) controlling HIV-1 transcription could be a
target of this protein bearing E3 ubiquitin protein ligase activity
in our system. Since RNF125/TRAC-1 had a weak down-
modulatory effect on CMV and HSV TK promoter activity, the
target protein of RNF125/TRAC-1may also be slightly involved
in controlling CMV and TK transcriptions. Further studies to
identify target candidates are needed and this approach could
develop a novel therapeutic intervention to suppress viral load in
HIV-1-infected individuals.
Materials and methods
Cells
PBMCs of healthy donors were separated on Ficoll-Hypaque
gradients. The CD4+ T-cell fraction was isolated from PBMCs
by depleting non-CD4+ T cells, as previously described
(Horikoshi et al., 2002). Subsequently, the resting CD4+ T-cell
fraction was obtained by depleting CD25+ CD4+ T cells and
further separated into 2 T-cell subsets (CD38+ and CD38−), as
previously described (Horikoshi et al., 2002). These cells were
cultured at 37 °C in RPMI-1640 medium supplemented with
10% heat-inactivated fetal calf serum (10% FCS–RPMI-1640).
293T cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% FCS. Jurkat T cells were
cultured in 10% FCS–RPMI-1640.
Oligonucleotide array analysis
CD4+ CD38+ and CD4+ CD38− T-cell subsets were cultured
in 10% FCS–RPMI-1640 for 3 days with or without re-
combinant IL-4 (R&D Systems) at 10 ng/ml, and total RNAwas
extracted. The activation level of CD4+ CD38 subsets after IL-4
stimulation was examined by phosphorylation of STAT6 by
Western blotting. cDNA synthesized from total RNA with the
SuperScript Choice System (GIBCO/BRL) was isolated by
phenol–chloroform extraction using Phase Lock Gels (Eppen-
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a template for in vitro transcription to generate biotinylated
antisense RNA. The in vitro transcription reaction was per-
formed using an Enzo Bioarray high-yield RNA transcription
labeling kit (Affymetrix), according to the manufacturer's
instructions. Biotinylated antisense RNA was fragmented and
hybridized to the microarrays. The arrays used in this study were
the GeneChip® Human Genome U133 Set (Affymetrix). The
arrays were washed and stained with streptavidin–R phycoer-
ythrin (Molecular Probes), and then with biotinylated goat anti-
streptavidin antibody (Sigma). The arrays were stained again
with streptavidin–R phycoerythrin. DNA chips were scanned
with a confocal laser scanner (Agilent) at a wavelength of
570 nm and data were analyzed with a commercial software
package (Microarray Suite 5.0, Affymetrix). IMS 3.0 and Data
Mining Tools 3.0 (Affymetrix) were used for data analysis.
Quantitative RT–PCR analyses
CD4+ CD38+ and CD4+ CD38− T-cell subsets were
stimulated with IL-4 at 10 ng/ml for 3 days, and total RNA
was extracted. To synthesize cDNA, 1.5 μg of RNAwas reverse-
transcribed using 200 units of SuperScript II RT (Invitrogen) and
0.5 μg of oligo-dT primer (Invitrogen). The cDNAwas used for
semi-quantitative PCR and real-time PCR analyses. Semi-
quantitative PCR conditions were as follows: initial denaturation
at 95 °C for 2 min, and 25 cycles consisting of 94 °C for 30 s,
55 °C for 30 s, 72 °C for 30 s, and a final elongation step at 72 °C
for 7 min. Real-time PCR analysis was performed using
Platinum SYBR green qPCR SuperMix-UDG (Invitrogen) on
an ABI PRISM 7900HT (Applied Biosystems). The conditions
were as follows: incubation at 50 °C for 30 min, followed by
95 °C for 10 min, and 45 cycles consisting of 95 °C for 15 s and
60 °C for 60 s. Real-time PCR products were also separated on a
1.5% agarose gel to visualize the formation of correct PCR
products.
Primers
Primers were purchased from FASMAC (Kanagawa, Japan).
The sequences of the primers used for quantitative RT–PCR
analysis were 5′-CGTGTGCCTTGAGGTGTTAC-3′ (sense)
and 5′-TCGGGTATTAAACGGCAAAG-3′ (antisense) for
RNF125/TRAC-1. The sequences of the primers for macrophage
colony-stimulating factor (M-CSF), IL-9 and β-actin were
previously described (Aharinejad et al., 2004; Oikawa et al.,
2004; Yang et al., 2004). The primers for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were purchased from
Toyobo Co. Ltd. (Osaka, Japan).
Plasmids
pNL4-3 (Adachi et al., 1986) was used as an HIV-1molecular
clone. pTat- and pLTR-Luc-containing sequences from pNL4-3
have been previously described (Kurosu et al., 2002). RNF125/
TRAC-1 cDNA for PCR amplification was synthesized using
total RNA extracted from IL-4-stimulated CD4+ T cells. PCRamplification was performed with KlenTaq LA DNA poly-
merase (Sigma), and the primers used were 5′-CTCGA-
GATGGGCTCCGTGCTGAGCAC-3′ (CL-1) and 5′-
GGATCCTGTGGTGTTCGAGTGATTCA C-3′ (CL-2). The
PCR products were cloned into pGEM-T Easy plasmid vector
(Promega) and sequenced. pGEM-T Easy/RNF125/TRAC-1was
cleaved with BamHI and XhoI, and ligated to similarly cleaved
pEF-BOS (Mizushima and Nagata, 1990), which permits the
addition of a Flag epitope tag at the carboxyl terminus. An
RNF125/TRAC-1 mutant, named C37A, was constructed by
PCR using pEF-BOS-RNF125/TRAC-1 as a template. Two
fragments were first amplified with pfu DNA polymerase
(Promega) using sense primer CL-1 together with 5′-GGCA-
CACGGCGGCGTCGAAGG-3′ (MU-2) and antisense primer
CL-2 together with 5′-CCTTCGACGCCGCCGTGTGCC-3′
(MU-1). These 2 individually amplified fragments were mixed,
and then further amplified by PCRwith the outside primers CL-1
and CL-2. The resulting fragment containing expectedmutations
was inserted into the pEF-BOS. Another RNF125/TRAC-1
mutant, named C37/40A, was similarly constructed, except for
PCR primers 5′-CTTCGACGCCGCCGTGGCCCTTG-3′
(MU-3) and 5′-CAAGGGCCACGGCGGCGTCGAAC-3′
(MU-4).
Reporter gene analysis
To establish 293T cells stably expressing a reporter gene,
293T cells were cotransfected with pLTR-Luc, a reporter gene
driven from herpes simplex virus thymidine kinase promoter
(pRL-TK) (Promega), a reporter gene driven from SV40
promoter (pRL-SV40) (Promega) or a reporter gene driven
from the cytomegalovirus promoter, together with a puromy-
cin-resistant plasmid. After culturing for 2 days, the cells
were further cultured with puromycin for 2 weeks. The
established 293T cells were transfected with various plasmids
using Lipofectamine 2000 (Invitrogen). Transfection was
carried out under the condition to equalize the total DNA
amount by adding empty plasmid DNA. Each assay was
repeated at least 3 times with cell lysates prepared by
independent transfection.
Western blotting
Western blotting was performed as previously described
(Kawata et al., 2003). The antibodies used were specific to
FLAG (F7425; Sigma), α-tubulin (T5168; Sigma), poly(ADP-
ribose) polymerase (PARP) (BD Biosciences), HIV-1 gp120
(ViroStat, Portland, ME) and RNF125/TRAC-1 (IMGENEX,
Corp., San Diego, CA).
Northern blotting
Northern blotting was performed as previously described
(Yamashita et al., 2005). The [α-32P]dCTP-labeled probe used
was specific to HIV-1 nef. The nef-specific probe was
synthesized using the full-length nef gene as a template with
the Random Prime Labeling System (Amersham Pharmacia).
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RNA oligonucleotides against RNF125/TRAC-1 were
designed according to the siRNA Target Finder website
(http://www.ambion.com/techlib/misc/siRNA_finder.html) and
were prepared with a Silencer siRNA Construction Kit
(Ambion, Austin, TX) (Kameoka et al., 2004). The siRNA
sequences used were as follows: 5′-AAGTGGACCTGTCCT-
TATTGC-3′ for RNF125/TRAC-1 siRNA 1 and 5′-AATACCC-
GATGAGAATCCAAG-3′ for RNF125/TRAC-1 siRNA 2. The
siRNA directed to GAPDH used as a control in this study was
supplied with the Silencer siRNA Construction Kit. The
expression plasmid, RNF125-escape(1), contains silent muta-
tions at the siRNA 1 recognition site, in which the wild-type
sequence 5′-AAGTGGACCTGTCCTTATTGC-3′ was substi-
tuted to 5′-AAATGGACGTGCCCTTACTGT-3′.
Production and infection of vesicular stomatitis virus
glycoprotein (VSVG)-pseudotyped recombinant HIV-1
VSVG-pseudotyped recombinant HIV-1, named VSVG/
HIV-1, which expresses the luciferase gene in place of the
viral nef gene (Chen et al., 1994; Connor et al., 1995; Fouchier
et al., 1997), was produced in 293Tcells, as previously described
(Kameoka et al., 2004). Viral stocks were quantified by HIV-1
Gag p24 antigen-capture enzyme-linked immunosorbent assay
(ELISA) (ZeptoMetrix Corporation) (Beauparlant et al., 1996).
VSVG/HIV-1 infection was performed as previously described
(Kameoka et al., 2004). Briefly, 1×106 CD4+ CD38 subsets
cultured with or without IL-4 at 10 ng/ml or PBMCs cultured
with phytohemagglutinin (PHA) (Sigma) at 2 μg/ml were
exposed to VSVG/HIV-1 (30 ng of p24 Gag) for 1 h at 37 °C.
After removing the virus, the cells were cultured with
recombinant IL-2 at 2 ng/ml (Pepro Tech) for 2 days. For
293T cells, the cells were infected with VSVG/HIV-1 (25 ng of
p24 Gag) and cultured for 24 h. Luciferase activity was then
measured.
Production and infection by the lentiviral vector
The gene transfer vector pWPT [cPPT-containing self-
inactivating (SIN) plasmid under the control of EF-1 promoter]
was used to generate pWPT-green fluorescent protein (GFP),
pWPT-RNF125/TRAC-1-FLAG, and pWPT-C37/40A-FLAG.
Briefly, 293T cells were cotransfected with the gene transfer
vector, packaging plasmid (pCMVΔR), and VSVG expression
plasmid (pMD2.G). At 2 days post-transfection, infectious
lentiviruses were harvested and concentrated by ultracentrifuga-
tion at 80,000×g at 4 °C for 2 h. PBMCs and Jurkat T cells were
adsorbed with the lentiviruses for 1 h and then cultured in the
medium.
Immunofluorescence staining
Cells infected with lentiviruses were fixed with 4% para-
formaldehyde for 20 min at room temperature. After permea-
bilization with 0.1% Triton X-100, cells were incubated withanti-FLAG antibody (F7425; Sigma) in Tris-buffered saline
(TBS) containing 1% bovine serum albumin. Subsequently, the
cells were incubated with Alexa Fluor 488-conjugated goat anti-
rabbit immunoglobulin G (Molecular Probes).
Proliferation assays
Growth studies were performed using the cell proliferation
assay kit (Chemicon International) according to the manufac-
turer's protocol. Briefly, Jurkat T cells infected with lentiviruses
were cultured for 48 h. Subsequently, 10 μl of WST-1/ECS
solution was added and incubated at 37 °C for 4 h. Optical
density at 450 nm was then determined using an ELISA reader.
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